Beckman Coulter acquires biotech company ValitaCell in analytics play

By The Science Advisory Board staff writers

September 16, 2022 -- Laboratory automation company Beckman Coulter Life Sciences has acquired biotech company ValitaCell for an undisclosed amount, according to a September 13 announcement from the companies.

Headquartered in Dublin, Ireland, ValitaCell provides analytical products and technologies for the biopharmaceutical industry intended to reduce new therapeutics' cost and time to market by empowering scientists with cell data and insights earlier in the drug discovery and development process.

"Together with Beckman Coulter Life Sciences, we will advance our shared ambition to accelerate and enable the sustainable manufacture of innovative biological medicines to bring them to market faster," said Dr. Jerry Clifford, co-founder and CEO of ValitaCell.

When it comes to immunoglobulin G quantification (IgG) assays, ValitaCell contends that its ValitaTiter product outperforms other techniques -- such as enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography (HPLC) -- in terms of speed and ease of use.

Jason Lanie, vice president of the biotechnology business unit at Beckman Coulter, noted that ValitaCell's "leading portfolio of products, including ValitaTiter, Quantum, CellAi, and ChemStress Clone Robustness complement Beckman Coulter's existing and future product portfolio and are designed with the same goal of providing faster cellular analysis while decreasing the risk of errors."

ValitaCell's Ireland locations, including Dublin and Galway, will remain operational and are anticipated to grow, the companies announced.

Beckman Coulter teams with Flownamics on bioprocess culture monitoring
Beckman Coulter Life Sciences has partnered with Flownamics to offer an automated, online solution for bioprocess culture monitoring and control, meeting...
Beckman, Scopio to partner on blood smear platforms
Beckman Coulter Diagnostics on Wednesday announced that it has partnered with Scopio Labs to accelerate adoption of Scopio's next-generation peripheral...
2021 Life Science Industry Award winners announced
New technologies make advancements in life science research possible, such as the development of drugs, therapeutics, and molecular diagnostics. This...
Early engagement with regulatory agencies is key to therapeutic development
Next-generation advanced therapies call for novel regulatory approaches, according to Mark Lane, PhD, vice president, development consulting and scientific...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter